ExodusPoint Capital Management’s AbCellera Biologics ABCL Stock Holding History

ExodusPoint Capital Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.87M	Buy	237,952 +95,206	+67%	+$465K	0.01%	846
2026 Q1	$498K	Buy	142,746 +29,678	+26%	+$107K	﹤0.01%	1191
2025 Q4	$387K	Buy	+113,068	New	+$505K	﹤0.01%	1246
2025 Q1	–	Sell	-281,795	Closed	-$826K	–	1396
2024 Q4	$826K	Buy	+281,795	New	+$785K	0.01%	1003
2024 Q2	–	Sell	-496,012	Closed	-$2.25M	–	1461
2024 Q1	$2.25M	Buy	496,012 +362,358	+271%	+$1.85M	0.02%	652
2023 Q4	$763K	Buy	+133,654	New	+$619K	0.01%	910
2023 Q3	–	Sell	-214,557	Closed	-$1.39M	–	1633
2023 Q2	$1.39M	Sell	214,557 -37,635	-15%	-$257K	0.01%	972
2023 Q1	$1.9M	Buy	252,192 +71,842	+40%	+$652K	0.02%	901
2022 Q4	$1.83M	Buy	180,350 +5,600	+3%	+$64.7K	0.03%	684
2022 Q3	$1.73M	Sell	174,750 -87,753	-33%	-$963K	0.02%	864
2022 Q2	$2.8M	Buy	262,503 +133,652	+104%	+$1.13M	0.03%	644
2022 Q1	$1.26M	Buy	128,851 +46,026	+56%	+$436K	0.02%	1016
2021 Q4	$1.18M	Buy	+82,825	New	+$1.26M	0.01%	983
2021 Q3	–	Sell	-29,972	Closed	-$659K	–	2031
2021 Q2	$659K	Buy	29,972 +20,729	+224%	+$572K	0.01%	1216
2021 Q1	$314K	Sell	9,243 -19,607	-68%	-$781K	﹤0.01%	1635
2020 Q4	$1.16M	Buy	+28,850	New	+$1.32M	0.01%	776

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

ExodusPoint Capital Management's ABCL Position: Q2 2026 in Review

ExodusPoint Capital Management increased its AbCellera Biologics (ABCL) stake by 67% in Q2 2026, buying an estimated $465K and bringing the position to 237,952 shares worth $1.87M. The position accounts for 0.01% of the portfolio, ranked #846.

ExodusPoint Capital Management first reported a position in ABCL in Q4 2020 and has held it in 16 quarters since. The position peaked at $2.8M in Q2 2022. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

ExodusPoint Capital Management held 237,952 shares of AbCellera Biologics worth $1.87M as of Q2 2026.
ExodusPoint Capital Management bought 95,206 AbCellera Biologics shares in Q2 2026, an estimated $465K.
AbCellera Biologics made up 0.01% of ExodusPoint Capital Management's portfolio in Q2 2026, its #846 holding.
ExodusPoint Capital Management first reported a position in AbCellera Biologics in Q4 2020 and has held it in 16 quarters since.
ExodusPoint Capital Management's AbCellera Biologics position peaked at $2.8M in Q2 2022.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.